People: Allergan plc (AGN.N)
16 Aug 2019
Dr. C. David Nicholson is Chief R&D Officer of the company since March 2015. Dr. Nicholson is the Chief R&D Officer of Allergan and has served in this role since March 2015. He joined Allergan (then known as Actavis) as Senior Vice President, Global Brands R&D in August 2014. Previously, he served as Chief Technology Officer and EVP, R&D for Bayer CropScience from March 2012 to August 2014; Vice President of Licensing and Knowledge Management at Merck from 2009 to December 2011; and Senior Vice President, responsible for Global Project Management and Drug Safety at Schering-Plough from 2007 to 2009. From 1988 to 2007, Dr. Nicholson held various leadership positions at Organon, where he most recently served as Executive Vice President, Research & Development and was a member of the company’s Executive Management Committee. He received a B.Sc. from the University of Manchester and his Ph.D. from the University of Wales.
|Total Annual Compensation, USD||3,859,660|
|Restricted Stock Award, USD||7,162,720|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||30,387|
|Fiscal Year Total, USD||11,052,800|